Evaluation of Cardiovascular Risk Among the Participants of the ESC Congress 2026 (ESC-CVRISK2026)
Cross-Sectional Assessment of Cardiovascular Risk Among ESC Congress 2026 Participants
The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health Plans which would include a cardiovascular and diabetes health check as part of a screening process for citizens.
In line with this call for public health diagnosis of CV health, the ESC is committed to raising awareness on the need for actions and proposes to offer complimentary tests to delegates at ESC Congress 2026 from 28-31 August 2026 in Munich, Germany.
The primary objective of the study is to screen the CV risk among the ESC Annual Congress 2026 attendees with a focus on healthcare professionals (HCP) and to stratify by primary or secondary prevention.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All attendees including healthcare professionals (doctors, nurses, etc.) attending the ESC Congress 2026 from 28 to 31 August 2026
- Subjects who declare that they are able to understand and give informed consent in English
- Adult subjects (≥ 18 years of age)
Exclusion Criteria:
- Subjects not willing to provide his/her consent to participate in the study.
- Subjects who are not suitable candidates for blood extraction.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Second Manifestations or Arterial Disease (SMART) risk score in patients with established cardiovascular diseases (CVD) at baseline
Time Frame: Baseline
|
Baseline
|
|
Systemic Coronary Risk Evaluation 2 (SCORE2) score in patients without established CVD at baseline
Time Frame: Baseline
|
Baseline
|
|
Level of agreement between self-perceived cardiovascular risk category and objectively assessed cardiovascular risk category based on the SCORE2 or SMART algorithm
Time Frame: Baseline
|
Baseline
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ESC-CVRISK 2026
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.